"Stavudine"@en . . "Stavudin"@en . . . . . . . . . "Estavudina"@en . . "1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine"@en . "Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA."@en . "A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. [PubChem]"@en . . . "Negligible"@en . . . . . . . . . . . . . "investigational"@en . "3056-17-5"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Human Immunodeficiency Virus"@en . . . "2',3'-Didehydro-3'-deoxythimidine"@en . . . "STV"@en . . "* 46 \u00B1 21 L"@en . "Sanilvudine"@en . . . . . . "Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%)."@en . "approved"@en . . "For the treatment of human immunovirus (HIV) infections."@en . . . "Stavudinum"@en . "Stavudine"@en . . . . . . . . "0.8-1.5 hours (in adults)"@en . . . . "Purna Chandra Ray, Jagan Mohana Chary Tummanapalli, Seeta Ramanjaneyulu Gorantla, \"Process for the Large Scale Production of Stavudine.\" U.S. Patent US20080312428, issued December 18, 2008."@en . . . . . . . . "Side effects include peripheral neuropathy tingling, burning, numbness, or pain in the hands or feet), fatal lactic acidosis has been reported in patients treated with stavudine (ZERIT) in combination with other antiretroviral agents, severe liver enlargement, inflammation (pain and swelling) of the liver, and liver failure."@en . "3'-Deoxy-2'-thymidinene"@en . . " "@en . . . . . . . . . . . . . . . "* Renal cl=272 mL/min [Healthy subjects receiving 80 mg PO] * 594 +/- 164 mL/min [HIV-infected adult and pediatric patients following 1-hour IV infusion] * 9.75 +/- 3.76 mL/min/kg [HIV- Exposed or -Infected Pediatric Patients(Age 5 weeks \u2013 15 years) following 1-hour IV infusion]"@en . . . . "d4T"@en . .